

# Enhancing Top-Down Analysis Using Chromophore-Assisted Infrared Multiphoton Dissociation from (Phospho)peptides to Protein Assemblies

Jean-François Greisch, Saar A.M. van der Laarse, and Albert J.R. Heck\*



Cite This: *Anal. Chem.* 2020, 92, 15506–15516



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

**ABSTRACT:** Infrared multiphoton dissociation (IRMPD) has been used in mass spectrometry to fragment peptides and proteins, providing fragments mostly similar to collisional activation. Using the 10.6  $\mu\text{m}$  wavelength of a  $\text{CO}_2$  laser, IRMPD suffers from the relative low absorption cross-section of peptides and small proteins. Focusing on top-down analysis, we investigate different means to tackle this issue. We first reassess efficient sorting of phosphopeptides from nonphosphopeptides based on IR-absorption cross-sectional enhancement by phosphate moieties. We subsequently demonstrate that a myo-inositol hexakisphosphate (IP6) noncovalent adduct can substantially enhance IRMPD for nonphosphopeptides and that this strategy can be extended to proteins. As a natural next step, we show that native phospho-proteforms of proteins display a distinct and enhanced fragmentation, compared to their unmodified counterparts, facilitating phospho-group site localization. We then evaluate the impact of size on the IRMPD of proteins and their complexes. When applied to protein complexes ranging from a 365 kDa CRISPR–Cas Csy ribonucleoprotein heterodecamer, a 800 kDa GroEL homo-tetradecamer in its apo-form or loaded with its ATP cofactor, to a 1 MDa capsid-like homo-hexacontamer, we conclude that while phosphate moieties present in crRNA and ATP molecules enhance IRMPD, an increase in the IR cross-section with the size of the protein assembly also favorably accrues dissociation yields. Overall, our work showcases the versatility of IRMPD in the top-down analysis of peptides, phosphopeptides, proteins, phosphoproteins, ribonucleoprotein assemblies, and large protein complexes.



## INTRODUCTION

Structural characterization of proteins by mass spectrometry is critically dependent on the fragmentation technique used. Collisional activation (CID/HCD)—the most commonly used technique—usually effectively dissociates small peptides and small denatured proteins. However, as the size of native compounds increases, the number of detected CID/HCD backbone cleavages decreases, making CID/HCD less favorable for top-down analysis.<sup>1</sup> This has led to the implementation of alternative dissociation techniques for larger proteins and native protein complexes making use of surfaces, electrons, and/or photons.<sup>2,3</sup>

One alternative activation method to CID/HCD is infrared multiphoton photodissociation (IRMPD). Applied for the first time to proteins—ubiquitin (8.6 kDa) and carbonic anhydrase (29 kDa)—already about 25 years ago,<sup>4</sup> IRMPD has significant advantages. These include a high level of control over the energy added by photons, no gas load in the vacuum of the mass analyzer, effective trapping of fragments at low RF voltages in multipoles, and the ability to induce the cleavage of certain disulfide bonds (as illustrated for an intact antibody in Figure S1).<sup>3,5,6</sup> Performed using a cost-effective continuous-wave (CW)  $\text{CO}_2$  laser, IRMPD is commonly described as nonselective—both parent ions and product ions are irradiated and dissociated—which can be beneficial because of the large


variety of product ions formed.<sup>7</sup> Applied to peptides and phosphopeptides in particular, IRMPD has been found to yield more extensive sequence information than CID/HCD, primarily because of its ability to form secondary and higher order fragments upon the absorption of multiple photons.<sup>8</sup> While essentially independent of ion optics, the effectiveness of IRMPD depends on irradiance, the number of excitable chromophores, as well as the channels open for energy redistribution and relaxation. For  $\text{CO}_2$  laser-driven IRMPD, some common absorbers are the  $\text{CH}_3$ -rocking, O–H bend, P–O, P–O–C, and P–O–P stretch vibrations, while de-excitation mainly involves collisional cooling at the pressures commonly achieved in multipoles.

Compared to peptides and denatured proteins, IRMPD of intact, quasi-native proteins and their assemblies is a more recent development that involves electrospraying compounds from solutions mimicking physiological conditions. To date, IRMPD dissociation into subunits has been demonstrated for

Received: August 11, 2020

Accepted: October 23, 2020

Published: November 12, 2020



avidin (AT, 64 kDa, 4-mer), GroEL (803 kDa, 14-mer), and CS<sub>2</sub> hydrolase (189 kDa, 8-mer) on a ToF<sup>9</sup> as well as glycogen phosphorylase (193 kDa, 2-mer), glutamate dehydrogenase (GDH, 334 kDa 6-mer), and  $\beta$ -galactosidase (GTD, 464 kDa, 4-mer) on an FT-ICR mass spectrometer.<sup>10</sup> While primarily yielding extensive sequence coverage for denatured proteins in conjunction with electron capture dissociation, IRMPD has also been found to yield valuable native top-down information—protein backbone cleavages—as demonstrated by Loo and co-workers for selected compounds.<sup>10</sup>

Building upon Muddiman's and Brodbelt's groups selective 10.6  $\mu$ m IRMPD of phosphopeptides over nonphosphorylated ones,<sup>8,11</sup> here, we chose to revisit the possibility of IRMPD enhancement by phosphate moieties (beyond phosphopeptides) to structurally probe peptides, native proteins, and protein assemblies. This broad focus is motivated by the absorption bands of molecules such as myo-inositol hexakisphosphate,<sup>12</sup> adenosine triphosphate (ATP),<sup>13</sup> and (deoxy)-ribonucleic acids (DNA and RNA)<sup>14</sup> about the 10,600 nm  $\equiv$  943 cm<sup>-1</sup> excitation line of a CO<sub>2</sub> laser. Over the past decade, gas-phase IR action (photodissociation) spectra corresponding to the 800–1900 cm<sup>-1</sup> range have been recorded using free-electron lasers for phosphocompounds ranging from protonated phosphothreonine, phosphotyrosine, phosphoserine,<sup>15–17</sup> 2'-deoxyadenosine-5'-monophosphate, and adenosine-5'-monophosphate cations<sup>18</sup> to deprotonated 2'-deoxynucleotide-5'-monophosphate anions<sup>19</sup> and nucleotide 5'-triphosphate anions.<sup>20</sup> All demonstrate substantial absorption around 943 cm<sup>-1</sup>. Consequently, following the demonstration that our IRMPD implementation on an EMR Q-Exactive Orbitrap can selectively dissociate phosphopeptides, we highlight the impact of noncovalent phospho-adducts on the IRMPD of peptides and native proteins. Applied to the native phospho-proteoforms of proteins, IRMPD yields distinct and enhanced fragmentation patterns, compared to their unmodified counterparts, facilitating phospho-group site localization. For increasing protein sizes and, therefore, IR absorption cross-sections, we show that 10.6  $\mu$ m IRMPD preferentially cleaves native proteins at aspartic acid (D, Asp) and glutamic acid (E, Glu) residues concurrently with an extensive concomitant golden ion pair—complementary b and y ions—formation.<sup>21</sup> This process, rationalized in terms of direct cleavage of the neighboring peptide bond by the aspartic acid proton, appears enhanced for IRMPD compared to CID/HCD likely due to the favorable absorption of Asp's and Glu's carboxylic moiety about 943 cm<sup>-1</sup>. We conclude by assessing IRMPD for noncovalent complexes and ribonucleoproteins ranging from a few hundred kDa to 1 MDa, making use of the fact that RNA and/or ATP bound to protein assemblies will also enhance IR absorption.

## EXPERIMENTAL SECTION


**Materials.** Peptide and protein standards were, unless described otherwise, purchased from Sigma-Aldrich (Merck KGaA, Germany). The phosphopeptides were custom-synthesized by Dris El Atmioui in the Huib Ova laboratory (LUMC, Leiden). Bora was expressed and phosphorylated *in vitro* by using the aurora kinase as described previously in ref 22. The CRISPR–Cas complex was provided by the Fineran group and expressed and purified as described in ref 23. The GroEL complex was expressed and purified as described in refs.<sup>24–26</sup> The AaLS virus-like capsid was provided by the

Hilbert group and expressed and purified as described in ref 27.

While peptides were simply solubilized in aqueous 150 mM NH<sub>4</sub>OAc (pH 6.8), all analyzed proteins were buffer exchanged to aqueous 150 mM NH<sub>4</sub>OAc (pH 6.8) using Amicon ultracentrifugal filters (Millipore, Merck KGaA, Germany) with a 10 kDa cutoff (5 kDa for ubiquitin). As typical for native electrospray ionization, protein and peptide concentrations in between 1 and 5  $\mu$ M were used.

Myo-inositol hexakisphosphate (IP6), also called phytic acid [50% (w/w) solution in H<sub>2</sub>O, Sigma-Aldrich #593648], was desalted using Supel-Select SCX columns. Immobilization was followed by extensive washing using a 750 mM NH<sub>4</sub>OAc solution. Elution involved a concentrated formic acid solution (pH 2), followed by neutralization using NH<sub>4</sub>OH. Following solvent evaporation, the eluate was resolubilized in water. We estimated IP6 losses upon desalting to be on the order of 50%. IP6 was added to concentrated 150 mM ammonium acetate solutions of peptides and proteins, resulting in 100:1 eq/eq excess. The optimal amount of IP6 added depends on the pH, ionic strength, and concentration of the binding peptide or protein. Typical adduct yields are displayed in Figure S7.


**Native Top-Down MS.** Top-down MS of native complexes was performed on an extended mass range (EMR) Q-Exactive orbitrap<sup>28</sup> (Thermo Fisher Scientific, Bremen, Germany), as schematized in Figure 1. All compounds were electrosprayed



**Figure 1.** Diagram of the coupling of the IR-laser to the EMR orbitrap. The main parameters altered to optimize detection for large complex subunits and fragments are displayed with an asterisk: \*1 for source-side deceleration of the ions of interest and \*2 for trapping in and ejection from the HCD cell (details in text).

with homemade gold-coated borosilicate capillaries using voltages in the 1.1–1.7 kV range. All spectra were acquired by setting the noise threshold parameter to 3.64. The standard resolution was 140,000 @  $m/z$  200. The extended  $m/z$  range of the EMR orbitrap used enables us to simultaneously record precursor ions, ejected subunits, high  $m/z$  product ions, and peptide fragments. Using IRMPD and low-pressure conditions, we can make full use of the long transient records, resulting in instrumental resolutions enabling isotopic resolution up to a few tens of kDa.

**Implementation of IRMPD.** For the IRMPD experiments, precursor ions were transferred to the HCD cell at a low kinetic energy [HCD direct eV setting = 1 (peptide) or 0 (proteins)] to prevent dissociation. The IRMPD mass spectra were acquired using a 10.6  $\mu$ m gated laser pulse of 80 ms (ti60HS Firestar, Synrad, Mukilteo, WA, U.S.A.) at laser powers reaching 95 W (57 W effective due to a 60% transmission into the HCD cell) as described in the next section. The HCD cell trapping and extraction parameters



**Figure 2.** IRMPD of the (a–c) singly phosphorylated SVTPKTVPASSAKTPSPAK peptide and (d–f) the quadruply phosphorylated SVpTPKTVPpTPASpSAKTpSPAK peptide. (a,d) Annotated charge-deconvoluted spectra highlighting fragments resulting from complete  $\text{HPO}_3$  loss (mass of  $\text{HPO}_3 = 79.9663$  Da, for a comparison with fragments retaining  $\text{HPO}_3$  see Figure S2), fragments labeled with \* have lost  $\text{H}_2\text{O}$ , precursor ions are annotated by a pink dot, (b,e) annotated peptide sequences with  $y^+$  ions in red and  $b^+$  ions in blue, (c,f) survival yield (blue) as a function of the maximum laser power (0–95% range) for the nonphosphorylated (P.) and the corresponding phosphorylated (phosphoP.) peptides (all fragments are taken into account). The complementary fragment fraction is displayed in green. 100 scans, 1 laser pulse of 80 ms per scan, (a–c)  $5.56 \times 10^{-11}$  mbar and (d–f)  $<5.00 \times 10^{-11}$  mbar  $\text{N}_2$  UHV readout, resolution of 140000 @  $m/z$  200. Enhancing peptide IRMPD using noncovalently attached IP6 as the chromophore.


were optimized for low-nitrogen collision gas pressures to achieve efficient detection of the subunits and fragments. Following mass selection in the linear quadrupole, the ions were transferred and stored in the HCD cell.

For the implementation of IRMPD on the EMR orbitrap, we used a design similar to the one previously used for UVPD and comparable to other CW setups.<sup>29,30</sup> A  $\text{BaF}_2$  viewport was added to the back of the HCD cell adjacent to the C-trap and a  $\text{BaF}_2$  window in lieu of the HCD cell electrometer. The laser beam divergence was compensated using an adjustable beam reducer consisting of zinc selenide lenses with 50 mm and –25 mm focal lengths. Coaxial adjustment of the 10.6  $\mu\text{m}$  laser beam with the HCD cell multipole, following its reduction by an aperture diameter of 2 mm, was achieved using a two mirrors–periscope configuration, which could be advantageously replaced by an optical fiber coupler.<sup>31</sup> As previously described,<sup>29</sup> the instrument Split Lens and HCD Exit test points were used to generate TTL trigger pulses using voltage comparators. An Arduino microcontroller was used both to provide the laser with gating TTL pulses and to ensure their synchronization 3 ms after injection into the HCD cell, as determined from processing the signals of the test points. Optimal operation was observed at very low nitrogen pressures (around  $5.5 \times 10^{-11}$  mbar readout on the UHV pressure gauge). Pressure was measured indirectly via monitoring the UHV readouts unscaled for the gas type. Effective pressures in the HCD cell are estimated to be in the  $10^{-5}$  to  $10^{-4}$  mbar range. To ensure a long enough observation time window, a detection delay (IonGun Time) of 150 ms was used without

significantly affecting the duty cycle at a 140,000 @  $m/z$  200 resolution characterized by 512 ms transients.

Differently, compared to the setup of Brodbelt and co-workers who implemented IRMPD on a LTQ orbitrap Velos,<sup>32</sup> here, no additional gasline was added to the C-trap to compensate for the low HCD cell pressure required to enable IRMPD. We instead optimized the setup to achieve efficient ion transfer at low kinetic energies. Among critical potential differences, the HCD cell DC offset relative to the C-trap—HCD direct eV parameter—was set to 0 (effective offset of 10 V) or 1 (effective offset of 1 V) whenever possible. The HCD cell DC offset of 1 was used to preclude collisional activation of the ions upon entry into the HCD cell and thereby ensure that all fragments detected resulted from the absorption of IR photons. The low pressure in the HCD cell C-trap assembly, although found to affect the transmission and detection of higher  $m/z$  precursors and product ions, improved their detection at high mass resolution.

For  $\text{MS}^2$  experiments on large protein assemblies, precursor ions of a single charge state were isolated using a 50–150  $m/z$  window.  $\text{MS}/\text{MS}$  experiments were performed with the following settings: 1 laser pulse at a 0–95 W CW intensity typically gated to 80 ms. By directing the original beam into the HCD cell, the beam has been measured to retain 60% of its intensity. Consequently, 80 ms laser pulses range from 0 J/pulse (0%) to 4.56 J/pulse (95%) for a beam diameter of 2 mm. Assuming a uniform energy distribution, the irradiances used range from 0 to 1814  $\text{W}/\text{cm}^2$  for a total pulse duration of 80 ms (fluence between 0 and 145  $\text{J}/\text{cm}^2$ , energy between 0



**Figure 3.** Charge-deconvoluted IRMPD mass spectrum of (a–c) angiotensin I doubly protonated precursor (exp.  $m/z$  978.776) complexed with an IP6 adduct ( $m/z$  1956.545, pink dot) and without ( $m/z$  1296.684, orange dot) (d–f) [Glu<sup>1</sup>-fibrinopeptide B doubly charged (exp.  $m/z$  1115.772) precursor with an IP6 adduct ( $m/z$  2230.537, pink) and without an IP6 adduct ( $m/z$  1570.676, orange). (a,d) The  $m/z$  gap between the ions retaining partially photofragmented IP6, immediately to the left of the precursors with IP6 (pink), and the bare precursors (orange) allows for easy rejection of ions carrying residual IP6 fragments. (b) Annotated angiotensin I and (e) [Glu<sup>1</sup>]-fibrinopeptide B structures with detected  $y^+$  ions in red and  $b^+$  ions in blue. (c,f) Relative abundances of precursors with IP6 (red), precursor without IP6 (blue), and sequence informative fragments (green) upon IRMPD of (c) angiotensin I and (f) [Glu<sup>1</sup>]-fibrinopeptide B, with and without IP6 adduct at different pulse energies.  $\sim 1000$  scans, 1 laser pulse of 80 ms per scan,  $7.98 \times 10^{-11}$  mbar N<sub>2</sub> UHV readout, 140,000 @  $m/z$  200 resolution.

and 4.56 J/pulse, and % maximum laser intensity from 0 to 95).


**Data Analysis.** Processing of the fragmentation spectra involved conversion of the raw files to mzML. We used the MSDeisotope python library (Joshua Klein, Boston University CBMS) with minimum\_score = 2.0 and mass\_error\_tolerance = 0.02 for peptides and minimum\_score = 10.0 and mass\_error\_tolerance = 0.02 for all proteins except Bora to generate charge deconvoluted—all ions are 1<sup>+</sup>—spectra with all the isotopic peaks retained.<sup>33,34</sup> For Bora, Xtract, as implemented in Thermo Xcalibur 4.2.28.14 (Thermo Fisher Scientific), was used with S/N 1.5, Fit Factor 60%, and Remainder 5%. The fragment assignment involved LcMsSpectator<sup>35</sup> (Pacific Northwest National Laboratory) on the charged deconvoluted spectra generated by the MSDeisotope library. The accuracy threshold was set to 5 ppm for all assignments with the results exported as .tsv files for further analysis. Sequence assignments accommodated the major IRMPD ion types (b, y) without taking into account H<sub>2</sub>O and NH<sub>3</sub> neutral losses, except when explicitly mentioned.

## RESULTS

**Implementation of IRMPD on a Q-Exactive EMR Orbitrap.** The primary obstacle for using IRMPD in a Q-Exactive orbitrap HCD cell, as carried out in the present work, is collisional de-excitation which hinders efficient dissociation at normal operating pressures and temperatures.<sup>9</sup> Our implementation of IRMPD on a Q-Exactive EMR orbitrap is schematically depicted in Figure 1. We basically used a design similar to the one we previously reported for UVPD<sup>29</sup> (for details, see Experimental Section). For irradiances commonly

achieved by a 10–50 W CO<sub>2</sub> laser combined with a standard quadrupole ion trap, room-temperature dissociation efficiency drops between  $2.7 \times 10^{-4}$  and  $5.3 \times 10^{-4}$  mbar (uncorrected He pressure) because of effective collisional quenching at these pressures. At pressures in excess of  $1 \times 10^{-3}$  mbar, the dissociation efficiency is essentially zero in the absence of beam focusing.<sup>7,36,37</sup> Here, we tackled this issue by operating the HCD cell at quite low static pressures.

**Phosphopeptides.** As initially shown by Brodbelt et al., IRMPD can selectively fragment phosphorylated over nonphosphorylated peptides because of the larger absorption cross-section of the former at  $943 \text{ cm}^{-1}$ .<sup>8,11,32</sup> To test our IRMPD setup as implemented on the EMR orbitrap, we decided to first reassess these findings. In agreement with these earlier reports, we also observed dramatically enhanced IRMPD fragmentation of a variety of synthetic phosphopeptides over the corresponding nonphosphorylated peptides, as shown in Figures 2, S2, and S3 for the peptides [SVTPKTVTPASSAKT(p)SPAK, SV(p)TPKTV(p)TPAS(p)-SAKT(p)SPAK] and Figures S4–S6 [TPA(p)TPTSSAS, GNSP(p)TPVSRW, LSPA(p)TPTSEG]. At irradiances enabling fragmentation, IRMPD-driven metaphosphoric acid loss ( $-\text{HPO}_3$ ) led to fragments similar to those observed in HCD/CID. Optimal fragmentation yields reached values ranging from 90 to 100% for all phosphorylated peptides investigated, while this yield remained below 10% for their nonphosphorylated counterparts. Using the maximal irradiance currently available to us, only one nonphosphorylated peptide (GNSPTPVSRW, Figure S5) underwent some IRMPD (fragmentation yield of 35%), while its phosphorylated counterpart fully dissociated under identical conditions. The



**Figure 4.** IRMPD of native apo-colicin E9 DNase. (a) Charge-deconvoluted IRMPD MS spectrum of bare E9 [8+], (b) annotated charge-deconvoluted MS spectrum of the E9 protein with IP6 adduct [8+], note the different scales of the y-axis in (a,b). For the IRMPD of the E9 protein with IP6 adduct are depicted in (c) the observed annotated (b, y) fragment ion pairs with  $y^+$  ions in red and  $b^+$  ions in blue separately normalized. (d) The sequence coverage and (e) the crystal structure with the positive patches in blue [PatchFinderPlus (PFplus), <http://pfp.technion.ac.il>] and cleavages in yellow (PDB ID: 1fsj). 1000 scans, one pulse of 4.56 J over 80 ms per scan,  $6.02 \times 10^{-11}$  mbar  $N_2$  UHV readout, 140,000 @  $m/z$  200 resolution.

number of phosphate groups present on a peptide also affected the extent of fragmentation as seen in Figures 2 and S2, where we observed that a quadruply phosphorylated peptide fragments already at much lower irradiances than the corresponding singly phosphorylated peptide, whereas the nonphosphorylated counterpart hardly fragmented even at the highest irradiances. Overall, based on the fragments detected, IR activation at  $943\text{ cm}^{-1}$  very effectively cleaved the backbone of phosphopeptides, suggesting an efficient intramolecular energy redistribution leading to a nonpreferential cleavage site.


Taken together, the results are consistent with the earlier work published by Crowe and Brodbelt using a Finnigan LCQ-Duo ion trap mass spectrometer.<sup>8</sup> We considered this data as a clear benchmark to demonstrate that our IRMPD setup on the EMR orbitrap performed well.

Next, we sought to enhance IRMPD for nonphosphopeptides. Photodissociation can be enhanced using nonendogenous chromophores covalently attached to a peptide or protein of interest.<sup>38–41</sup> For  $CO_2$  laser-driven IRMPD, a chromophore of choice has been 4-methylphosphonophenylisothiocyanate (PPITC) attached to the N-terminus of the peptides.<sup>42</sup> As already mentioned by Brodbelt and co-workers, the idea of attaching chromophores via noncovalent interactions is, however, far more appealing and potentially more generally applicable than derivatization.<sup>43</sup> We therefore explored here myo-inositol hexakisphosphate as a noncovalent adduct (IP6,  $C_6H_{18}O_{24}P_6$ , 659.861 Da) to enhance the IRMPD of nonphosphorylated peptides. Based on the available literature, IP6 can be expected to interact preferentially with basic residues such as arginine and lysine.<sup>44,45</sup> We observed that the IRMPD efficiency was enhanced by about 1 order of magnitude at optimal irradiances. Use of the adduct did not hinder the analysis: we could easily disentangle the precursor ions carrying the adduct both from the bare precursor and fragments ions upon charge deconvolution, as illustrated in Figures 3 and S8. The absence of a detectable phosphate

transfer from the adduct to the peptide fragments also considerably facilitated the interpretation of the peptide fragment ion spectra.

The first peptide we investigated (Figure 3a–c) was angiotensin I (Table S1). IRMPD at the maximal laser power (4.56 J/pulse) of angiotensin I doubly protonated ions ( $m/z$  648.858) and yielded barely detectable fragments: all but one had a relative intensity below 0.06% compared to the precursor ion. Photoactivation of the [angiotensin I-IP6] complex ( $m/z$  978.776, 2.4 J/pulse), on the other hand, did lead to extensive fragmentation. Besides the precursor ion (charge-deconv.  $m/z$  1956.545), IRMPD yielded protonated angiotensin I (charge-deconv.  $m/z$  1296.684), b-ions from  $b_2^+$  to  $b_6^+$  up to  $b_9^+$ , and the complete y-ion series from  $y_3^+$  to  $y_9^+$ . In other words, we achieved the full sequence coverage of angiotensin I by IRMPD of the peptide-IP6 noncovalent complex.

As a second example (Figure 3d–f) of IP6-enhanced IRMPD of a peptide, we used human [Glu<sup>1</sup>]-fibrinopeptide B (glufib). Similar to angiotensin I (Figure 3a–c) and bradykinin (Figure S7), IRMPD of the doubly charged ions ( $m/z$  785.842) at maximal laser power yielded barely detectable fragments, whose relative intensity compared to the precursor ions was, for all but one, below 1.4%. IRMPD of glufib complexed with IP6 ( $C_6H_{18}O_{24}P_6$ , 659.861 Da) led, on the other hand, to extensive fragmentation of glufib. Besides the precursor ion (charge-deconv.  $m/z$  2230.537), IRMPD yielded protonated glufib (charge-deconv.  $m/z$  1570.676), b-ions from  $b_4^+$  to  $b_{11}^+$  with the exception of  $b_6^+$  and  $b_9^+$ , and the complete y-ion series from  $y_1^+$  to  $y_{11}^+$  with the exception of  $y_5^+$ . Hence, IRMPD of the IP6 complex resulted in full sequence coverage of [Glu<sup>1</sup>]-fibrinopeptide B. As was the case for all the peptides studied (including bradykinin, Figure S8), mass separation enabled easy rejection of the intact peptides retaining partially dissociated IP6. Data analysis was further



**Figure 5.** Charge-deconvoluted IRMPD mass spectra of Bora. (a) IRMPD on unphosphorylated Bora produces no fragments, (b) IRMPD mass spectra of multiple phosphorylated Bora. (c) Assigned b/y fragment ions for Bora(HPO<sub>3</sub>)<sub>4</sub>. (d) Bora(HPO<sub>3</sub>)<sub>4</sub> sequence coverage (only b and y ions) with the phospho-sites marked as red circles. (e) Relative abundances of the precursor without IP6 (blue) and sequence informative fragments (green) upon IRMPD of Bora (P.) and its phospho-proteoforms. 1000 scans, one pulse of 4.56 J over 80 ms per scan,  $6.24 \times 10^{-11}$  mbar N<sub>2</sub> UHV readout, 140,000 @  $m/z$  200 resolution.

considerably facilitated by the absence of peptide fragments, retaining IP6 or fragments thereof.

**Enhancing Protein IRMPD Using Noncovalently Attached IP6 as the Chromophore.** We next applied this chromophore-assisted approach to native proteins not directly amenable to IRMPD by investigating the enhancement of their 10.6  $\mu\text{m}$  absorption cross-section by the complexation of myo-inositol hexakisphosphate.

Of note, quite a substantial part of all proteins are expected to interact with molecules containing a phosphate group.<sup>46</sup> Often, the interacting phosphate takes part in a network of hydrogen bonds with atoms from the backbone forming a geometrically and energetically favorable scaffold.<sup>47</sup> A positive electrostatic potential promoting the binding of negatively charged phosphate groups such as those found in DNA and RNA is another common feature.<sup>47</sup> In our study of chromophore-enhanced IRMPD of native proteins, we therefore targeted the bacteriocin colicin E9, which is a DNase (Figure 4) harboring a positive patch susceptible to bind DNA and thus possibly also IP6. Indeed, noncovalent complexes of E9 with a single molecule of IP6 could be generally made and ionized by nanoelectrospray. Next, we investigated whether IP6 could enhance absorption and lead to energy transfer to the protein backbone on IRMPD.


Colicin E9, which is a bacteriocin produced by *Escherichia coli*, acts against competing *E. coli* by cleaving their DNA at specific locations. We mass-selected the 8+ charge state of the native apoprotein (without the Zn<sup>2+</sup> cofactor), which corresponds to a compact conformation. In Figure 4a, close

to no fragments are detected upon IRMPD of bare Colicin E9, while nearly 3 orders of magnitude increase in fragment yield was observed upon IP6 binding (Figure 4b). Interestingly, the most abundant fragments were (b, y) golden pairs (Figure 4c), thereby facilitating the identification. An analysis of the cleavage sites established a weak correlation between the fragments formed and the positive patch that likely serves as the binding site of the IP6 chromophore (displayed as a blue patch in Figure 4e). Similar to peptides, extensive fragmentation of endonuclease Colicin E9 and mAmetrine (Figure S9) occurs under the low-pressure conditions achievable on our instrumentation consistently with intramolecular vibrational energy redistribution (IVR) on timescales significantly shorter than collisional deactivation.

The high dissociation yields and the absence of IP6 adducts on the generated fragments considerably increase the potential of IRMPD for native proteins in the low- to mid-size range.

**Phospho-Proteins.** Following the use of noncovalent myo-inositol hexakisphosphate (IP6) adducts to enhance the IR absorption cross-section of peptides and native proteins, we focused on proteins harboring different phospho-proteoforms. The potential of IR spectroscopic methods to identify posttranslational modifications has been recently reviewed by Maitre and co-workers.<sup>17</sup>

Because of the loss of labile phospho-groups on collisional activation in the gas-phase, native phospho-proteoforms are particularly challenging to characterize using thermal activation MS methods, such as CID and IRMPD. Herein, we nevertheless demonstrate that valuable information can be



**Figure 6.** (a–c) IRMPD and CID/HCD of SCR1104 CRISPR–Cas Csy complex, see Table S2 for additional information. (a) IRMPD of (black envelope, 38<sup>+</sup>) precursor (pr.) leading to the ejection of Csy3 (green, 21<sup>+</sup>) with an isotopically resolved peak (inset, 20<sup>+</sup>) and Cas6f (purple, 17<sup>+</sup>), as well as a subunit fragment (red, 18<sup>+</sup>), and the formation of pr.–Cas6f (purple, 40<sup>+</sup>), pr.–fragment (red, 30<sup>+</sup>), pr.–Cas6f (purple, 23<sup>+</sup>), pr.–Csy3 (green, 19<sup>+</sup>). Collision energy = 0 direct eV, 1.44 J/pulse,  $p(\text{N}_2) = 1.29 \times 10^{-10}$  mbar, resolution 140k @  $m/z$  200, no micro-scan averaging. (b) CID/HCD of (black envelope, 38<sup>+</sup>) precursor leading to the ejection of Csy3 dimer (blue, 22<sup>+</sup>), Csy1 (red, 20<sup>+</sup>), Csy3 (green, 15<sup>+</sup>) with zoom-on isotopic distribution (inset, 20<sup>+</sup>), and Cas6f (purple, 10<sup>+</sup>). Collision energy = 120 direct eV, no laser,  $p(\text{N}_2) = 3.22 \times 10^{-10}$  mbar, resolution 140k @  $m/z$  200, 10 micro-scans averaging. (c) Structural model of an analogous CRISPR–Cas complex (PDB ID: 5UZ9). (d–g) IRMPD of GroEL loaded with ATP. (d) Structural model of GroEL (PDB ID: 4AAS). (e) Comparison of the mass spectra of (black) bare GroEL and (blue) GroEL loaded with ATP. (f) IRMPD of bare GroEL for different irradiances and laser shot numbers. Collision energy = 1 direct eV,  $p(\text{N}_2) = 1.27 \times 10^{-10}$  mbar, resolution 140k @  $m/z$  200, no micro-scans averaging. (g) IRMPD of GroEL loaded with ATP at different irradiances. Collision energy = 1 direct eV,  $p(\text{N}_2) = 1.61 \times 10^{-10}$  mbar, resolution 140k @  $m/z$  200, no micro-scans averaging.

gained from the native top-down analysis of phospho-proteforms by IRMPD on an orbitrap. Our hypothesis was based on the trend we observed for phosphopeptides. We expect that also for native proteins, the more phosphate groups they carry, the more extensive the IR absorption will be, with consequently richer and more informative fragmentation spectra.

Here, we focused on the 17.5 kDa N-terminal fragment of the mitotic regulator Bora.<sup>48–50</sup> Following expression and purification, we phosphorylated Bora in vitro using the aurora A kinase (AurA) as described in detail previously.<sup>51</sup> Bora has been determined to display an average of three phospho-groups under stationary (“equilibrium”) reaction conditions. Of the 8 phospho-sites determined for the Bora studied here,<sup>22</sup>

two, Ser59 and Thr144, have been determined to be specific AurA targets largely complying with the AurA substrate recognition sequence on Bora and therefore highly abundant.<sup>52</sup> Two additional moderately phosphorylated sites, Ser4 and Ser123, could also be identified from quantitative liquid chromatography with tandem mass spectrometry experiments.<sup>22</sup>

As for Colicin E9 DNase (Figure 4), only a minimal fragmentation of Bora (Figures 5, S10, and S11) occurs in the absence of phospho-groups (Figure 5a). A comparison of the charge-deconvoluted IRMPD mass spectra of the three most abundant phospho-Bora signals is displayed in Figure 5b. Under identical IRMPD activation conditions, the fragmentation yields continuously increase from Bora(PO<sub>4</sub>)<sub>2</sub>, Bora-

(PO<sub>4</sub>)<sub>3</sub>, to Bora(PO<sub>4</sub>)<sub>4</sub>, although not as markedly as between a bare and a phosphorylated compound (Figure 5e). Fragments are primarily b-ions with the most intense high *m/z* ions formed upon the cleavage of N-terminal or C-terminal of an Asp residue (Figure 5c). Although the fragmentation patterns display marked differences directly related to the number of phospho-groups (Figure 5e), all three are consistent with the phosphorylation of Ser59 unambiguously assigned from Bora(PO<sub>4</sub>)<sub>4</sub> data (Figure 5d). The limited sequence coverage currently precludes unambiguous assignments beyond Ser59.

In the present section, we have shown that IRMPD can yield structural information beyond amino acid sequence cleavages. Characterizing the structural features responsible for biological function calls for techniques leading to selective dissociation of or near the functional region. One way to achieve this is to design or make use of fragmentation sensitizers directly binding or affecting the region of interest. We have shown that phospho-groups potentially can serve this purpose; other candidates are O-sulfation groups.<sup>17</sup>

**IRMPD of Large Complexes.** In this last section, we examined whether IRMPD can be applied to high-mass protein complexes. We investigated the supportive role of phosphate moieties in IRMPD and also hypothesized that possibly very large complexes already absorb sufficiently well because of the very large number of absorbing oscillators present. We thereby pursue the integration of native IRMPD and top-down proteomics initiated for large protein assemblies by Robinson and co-workers<sup>9</sup> and Loo and co-workers.<sup>10</sup> In short, we demonstrate in this section that the presence of phosphate groups (e.g., also in the form of RNA or ATP) and larger size are indeed beneficial for efficient IRMPD of the 346 kDa CRISPR–Cas Csy (aka type I–F) ribonucleoprotein complex (Figure 6a–c), the 800 kDa GroEL 14-mer chaperone (Figure 6d–g) both with and without ATP co-factors bound, and ultimately, the 1 MDa wt-AaLS virus-like synthetic nanocontainer (Figure S13).

The CRISPR–Cas Csy ribonucleoprotein complex (In Figure 6a–c) grants adaptive immunity to the *Pectobacterium atrosepticum* SCRI104<sup>53</sup> and is capable of homology-directed detection as well as degradation of invading genetic elements.<sup>54</sup> A 60-nucleotide crRNA strand serves as the backbone for the subunits of the CRISPR–Cas Csy complex. While the *P. atrosepticum* SCRI104 CRISPR–Cas Csy complex has been extensively structurally characterized, its crRNA phosphate moiety containing the backbone makes it an ideal candidate to assess the chromophore-enhanced IRMPD of large complexes. In Figure 6a, we illustrate the photodissociation of the precursor ion of mass 346,962 ± 30 Da and charge distribution [42<sup>+</sup>–35<sup>+</sup>]. The dissociation was highly asymmetric—the intact subunits leaving the complex took a significant part of the charge with them, suggesting extensive unfolding of the ejected subunits. In Figure 6a, we assign the fragment distribution to two intact subunits—Cas6f [20<sup>+</sup>–13<sup>+</sup>] and Csy3 [24<sup>+</sup>–13<sup>+</sup>]—as well as their complementary high mass products—pr-Csy3 [23<sup>+</sup>–16<sup>+</sup>] and pr-Cas6f [26<sup>+</sup>–19<sup>+</sup>] & [40<sup>+</sup>–36<sup>+</sup>]. A lower intensity [18<sup>+</sup>–13<sup>+</sup>] fragment was detected as well as a high-intensity high mass [33<sup>+</sup>–25<sup>+</sup>] product ion which remains currently unassigned. Analysis of fragments generated in a separate experiment led to the detection of a sequence tag corresponding to Csy1 (Figure S12). Interestingly, while the charge distributions of Csy3 and pr-Csy3 complement each other yielding the charge distribution of the precursor, the charge distribution of the Cas6f complementary high mass

product (pr-Cas6f) is bimodal. The lower charge pr-Cas6f component matches the detected Cas6f distribution, while the higher charge pr-Cas6f component appears to correspond to Cas6f being ejected close to neutral. The origin of this difference, while currently unknown, is expected to be related either to the coexistence of two competing activation mechanisms (e.g., direct protein activation vs crRNA mediated) or two conformations of the complex. Comparison of IRMPD (Figure 6a) with CID/HCD (Figure 6b) highlights behavioral differences. The charge distributions of ejected subunits are systematically higher for IRMPD than for CID/HCD. Consequently, IRMPD-ejected subunits are concentrated in the low *m/z* range, where instrumental resolution is optimal and enable isotopic resolution while the complementary high *m/z* products are shifted to a higher *m/z* where they overlap less. IRMPD and CID/HCD also differ in the relative abundance of the ejected subunits: the ratio Cas6f to Csy3 is about 10 times higher for IRMPD than for CID/HCD possibly because of phosphate-related local hotspots. Finally, using CID/HCD, we detected the Csy1 subunit intact and a Csy3 dimer, while using IRMPD, we detect Csy1 only as fragments and no dimer. Overall, although both activation methods provide somewhat similar fragment ions, IRMPD does not fully give the same MS/MS spectra as CID/HCD for the SCRI104 CRISPR–Cas Csy complex, and thus, complementary structural information can be extracted.

Next, we subjected the *E. coli* GroEL chaperonin to IRMPD. GroEL is a 800 kDa homo-14-mer,<sup>55</sup> arranged in two heptameric rings stacked back to back (Figure 6d) that has become one of the standard samples used in native MS.<sup>56–60</sup> To assist substrate folding, GroEL requires ATP binding, which is known to be highly cooperative.

In Figure 6e–g, we depict and compare the IRMPD mass spectra of bare and ATP-loaded GroEL. As can be seen from the overlapping spectra (Figure 6e) of bare GroEL and GroEL incubated with ATP, up to 7 ATPs can be detected bound to GroEL. While displaying similar IRMPD dissociation patterns (Figure 6f,g)—the GroEL monomers are ejected intact without bound ATP—IRMPD of ATP-loaded GroEL occurs at lower irradiances compared to bare GroEL. About a third of the bare GroEL irradiance is needed to almost completely dissociate ATP-loaded GroEL. It is interesting to note that the charge distributions of the GroEL monomers are bimodal in the high-energy IRMPD mass spectra of the bare and ATP-loaded GroEL ions on par with a sequential ejection of subunits: the first subunit rips more charge from the precursor than the second.

Finally, to further extend the mass range, we proceeded to perform IRMPD of wt-AaLS, a homo-hexacontamer virus-like capsid (60-mer) formed by lumazine synthase (Figure S13). IRMPD of AaLS yields the intact subunit as well as the complementary fragment. While UVPD can lead to both intact ejection and fragmentation of the subunits, IRMPD primarily results into their intact ejection at the irradiances used, very similar to what is observed in CID/HCD.<sup>61</sup> The subunits ejected on IRMPD carry off on average more charges than on UVPD under identical conditions.<sup>23</sup>

**Mechanistic Aspects of IRMPD.** In summary, we demonstrated that IRMPD of (phospho)peptides, native (phospho)proteins, and protein assemblies is possible in the HCD cell of a Q-Exactive orbitrap mass spectrometer operated at low pressure. In the present section, we attempt to provide a physicochemical rationale for our observations.



Under high-vacuum conditions and in the absence of an IR chromophore, evidence favors that IRMPD occurs by excitation via the coherent quasiresonant-stepwise mechanism.<sup>62</sup> In the  $\sim 10^{-5}$  to  $10^{-4}$  mbar HCD cell of a Q-Exactive orbitrap, IRMPD conditions tend to deviate from those required for the coherent quasiresonant-stepwise excitation mechanism to operate. Under standard HCD cell conditions, collisional deactivation completely quenches IRMPD. Adjusting the pressure to an optimal trade-off between ion signal abundance and IRMPD efficiency is therefore essential for optimal operation. Under our pressure and irradiance conditions, both extensive backbone cleavage and partial retention of phospho-groups are observed. We hypothesize that the phospho-groups influence IRMPD in two ways: (1) the total absorption cross-section is increased, leading to a higher vibrational excitation, and (2) phospho-sites can act as localized hotspots which, despite fast IVR, may affect the relative abundance of the detected fragments.


Another factor to account for is carboxylic acid groups. While intrinsic chromophores such as the carboxylic groups of aspartic and glutamic acid enhance  $943\text{ cm}^{-1}$  IR absorption, they are also involved in the formation of so-called golden pairs, an efficient dissociation channel, as inferred from the intensity of the detected fragments.

As compounds' size increases, the amount of internal energy required to unfold native compounds and/or separate noncovalently bound fragments increases. Because of intramolecular energy redistribution and the requirement for an ever-larger number of collisions or collisions at higher energy, CID becomes ineffective for the top-down characterization of native compounds as compounds' size increases. Furthermore, with CID/HCD necessarily impacting surface residues more than the buried ones, native top-down characterization of proteoforms by CID/HCD can be hindered by the loss of labile posttranslational modifications located on the compound's surface. IRMPD, on the other hand, directly benefits from the increase of the  $10.6\text{ }\mu\text{m}$  absorption cross-section of proteins with the protein size, the increased number of aspartic and glutamic acid residues, and a rather spatially homogeneous excitation of the residues in the absence of extrinsic chromophores. IRMPD is therefore potentially less likely to induce the loss of labile posttranslational modifications located on the compound's surface, at irradiances enabling competition between unfolding, backbone fragmentation, and loss of labile groups. Our data suggest that for native compounds, IRMPD (combined or not with CID/HCD) may prove a suitable approach to characterize compounds carrying phospho-groups. A summary of our findings in terms of absorption cross-section is depicted in Figure 7.

Finally, for very large native complexes, achievable irradiances result, despite the increase of the  $10.6\text{ }\mu\text{m}$  absorption cross-section with protein size, into a slow energy buildup. In these systems, subunit ejection is the primary dissociation channel with, as demonstrated by Robinson and co-workers,<sup>57</sup> an asymmetric charge partitioning, indicative of subunit unfolding. Although largely overlooked, the present results suggest a bright future for the pulsed- $\text{CO}_2$  excitation of native compounds.

## CONCLUSIONS

In the present work, we demonstrate the capabilities of IRMPD implemented in the HCD cell of an orbitrap mass spectrometer for compounds ranging from phosphopeptides,



**Figure 7.** Schematic summary of the impact of molecular size, the number of phospho-groups, and the number of D and E residues on the  $10.6\text{ }\mu\text{m}$  absorption cross-section of peptides and proteins. The dependence of the IR absorption cross-section on the # of residues and composition is depicted as a wedge: in the absence of phosphate groups (gray wedge), the  $10.6\text{ }\mu\text{m}$  absorption cross-section increases with the # of residues, and all the more so that the fraction of D and E residues is large. On phosphorylation [addition of  $n \times \text{HPO}_3$  resulting in the formation of  $n$  phosphate group(s)], an absorption jump is seen: transition from the gray wedge to a red one (or for compounds consisting only of phosphates from the dashed circle to a colored one). As the number of phospho-groups increases, we transition to edges characterized by ever-larger  $10.6\text{ }\mu\text{m}$  absorption cross-sections.

native proteins, to large supramolecular assemblies. Specifically, we address dissociation yield issues by operating our setup at low nitrogen pressure and by compensating for low absorption cross-sections at  $10.6\text{ }\mu\text{m}$  by using phosphate-based chromophores.

Additionally, while earlier reported IRMPD work primarily focused on peptides and denatured proteins, we expanded IRMPD substantially by demonstrating its applicability to native phospho- and phospho-adduct proteins. A multiple-fold enhancement of dissociation was recorded for phospho-compounds compared to bare ones. We also showed that preferential cleavages similar to those observed in CID and SID took place. Under optimal IRMPD conditions, phospho-groups are retained, despite the fact that they act as IR-chromophores and, thereby, enhance dissociation. When applied to large protein complexes ranging from a CRISPR-Cas Csy complex, a (ATP-loaded) GroEL complex, to a 1 MDa virus-like capsid, IRMPD leads to the ejection of highly charged intact subunits. The unfolding induced by IRMPD may therefore be beneficial to native top-down proteomics on use in conjunction with activation techniques such as UVPD.

Combined with the recently demonstrated coupling of a  $\text{CO}_2$  laser to an orbitrap via an IR optical fiber,<sup>31</sup> the present results support a bright future for a native top-down chromophore-enhanced IRMPD MS on commercial instruments beyond FT-ICRs.

## ■ ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.analchem.0c03412>.

Peptides and proteins, IRMPD of monoclonal antibody, detailed assignment of phosphopeptides fragments, formation and fragmentation of peptides carrying IP6, detailed fragmentation analysis of phospho-Bora, large protein complexes, IRMPD mass tag identification of a CRISPR–Cas protein, and IRMPD of the Mega-Dalton AaLS complex (PDF)

## ■ AUTHOR INFORMATION

### Corresponding Author

Albert J.R. Heck – Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, 3584CH Utrecht, The Netherlands; Netherlands Proteomics Center, 3584CH Utrecht, The Netherlands; [orcid.org/0000-0002-2405-4404](https://orcid.org/0000-0002-2405-4404); Email: [a.j.r.heck@uu.nl](mailto:a.j.r.heck@uu.nl)

### Authors

Jean-François Greisch – Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, 3584CH Utrecht, The Netherlands; Netherlands Proteomics Center, 3584CH Utrecht, The Netherlands

Saar A.M. van der Laarse – Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, 3584CH Utrecht, The Netherlands; Netherlands Proteomics Center, 3584CH Utrecht, The Netherlands

Complete contact information is available at: <https://pubs.acs.org/doi/10.1021/acs.analchem.0c03412>

### Author Contributions

The paper was written through contributions of all authors.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

We thank the members of the Heck laboratory for the support, especially Arjan Barendregt. Dris El Atmioui of the Huib Ova laboratory (LUMC, Leiden) provided the synthetic phosphopeptides. Donald Hilvert's group (ETH Zürich, Switzerland) and Stephan Tetter in particular are acknowledged for providing the AaLS sample. Peter C. Fineran's group (University of Otago, New-Zealand), Robert D. Fagerlund, and Howard W. R. Maxwell in particular are acknowledged for supplying the CRISPR–Cas Csy (type I–F Cascade) complex. We kindly acknowledge Dietmar Reusch and Markus Habegger from Roche, Penzberg, Germany for supplying Trastuzumab. This research received funding through The Netherlands Organization for Scientific Research (NWO), projects ENPPS.LIFT.019.001, SPI.2017.028, and TTW.15575.

## ■ REFERENCES

- (1) Wysocki, V.; Jones, C.; Galhena, A.; Blackwell, A. *J. Am. Soc. Mass Spectrom.* **2008**, *19*, 903–913.
- (2) Macias, L. A.; Santos, I. C.; Brodbelt, J. S. *Anal. Chem.* **2020**, *92*, 227–251.

- (3) den Boer, M. A.; Greisch, J.-F.; Tamara, S.; Bondt, A.; Heck, A. J. R. *Chem. Sci.* **2020**, DOI: 10.1039/D0SC03438J.
- (4) Little, D. P.; Speir, J. P.; Senko, M. W.; O'Connor, P. B.; McLafferty, F. W. *Anal. Chem.* **1994**, *66*, 2809–2815.
- (5) Rush, M. J. P.; Riley, N. M.; Westphall, M. S.; Coon, J. J. *Anal. Chem.* **2018**, *90*, 8946–8953.
- (6) Ganisl, B.; Breuker, K. *ChemistryOpen* **2012**, *1*, 260–268.
- (7) Payne, A. H.; Glish, G. L. *Anal. Chem.* **2001**, *73*, 3542–3548.
- (8) Crowe, M. C.; Brodbelt, J. S. *J. Am. Soc. Mass Spectrom.* **2004**, *15*, 1581–1592.
- (9) Mikhailov, V. A.; Liko, I.; Mize, T. H.; Bush, M. F.; Benesch, J. L. P.; Robinson, C. V. *Anal. Chem.* **2016**, *88*, 7060–7067.
- (10) Li, H.; Nguyen, H. H.; Ogorzalek Loo, R. R.; Campuzano, I. D. G.; Loo, J. A. *Nature Chem.* **2018**, *10*, 139–148.
- (11) Flora, J. W.; Muddiman, D. C. *Anal. Chem.* **2001**, *73*, 3305–3311.
- (12) He, Z.; Honeycutt, C. W.; Xing, B.; McDowell, R. W.; Pellechia, P. J.; Zhang, T. *Soil Sci.* **2007**, *172*, 501.
- (13) Khalil, F. L.; Brown, T. L. *J. Am. Chem. Soc.* **1964**, *86*, 5113–5117.
- (14) Siebert, T.; Guchhait, B.; Liu, Y.; Costard, R.; Elsaesser, T. J. *Phys. Chem. B* **2015**, *119*, 9670–9677.
- (15) Scuderi, D.; Bakker, J. M.; Durand, S.; Maitre, P.; Sharma, A.; Martens, J. K.; Nicol, E.; Clavaguera, C.; Ohanessian, G. *Int. J. Mass Spectrom.* **2011**, *308*, 338–347.
- (16) Correia, C. F.; Balaj, P. O.; Scuderi, D.; Maitre, P.; Ohanessian, G. *J. Am. Chem. Soc.* **2008**, *130*, 3359–3370.
- (17) Maitre, P.; Scuderi, D.; Corinti, D.; Chiavarino, B.; Crestoni, M. E.; Fornarini, S. *Chem. Rev.* **2020**, *120*, 3261–3295.
- (18) Wu, R. R.; He, C. C.; Hamlow, L. A.; Nei, Y.-w.; Berden, G.; Oomens, J.; Rodgers, M. T. *J. Phys. Chem. B* **2016**, *120*, 4616–4624.
- (19) Ligare, M. R.; Rijs, A. M.; Berden, G.; Kabeláč, M.; Nachtigallova, D.; Oomens, J.; de Vries, M. S. *J. Phys. Chem. B* **2015**, *119*, 7894–7901.
- (20) van Outersterp, R. E.; Martens, J.; Berden, G.; Steill, J. D.; Oomens, J.; Rijs, A. M. *Phys. Chem. Chem. Phys.* **2018**, *20*, 28319–28330.
- (21) Horn, D. M.; Zubarev, R. A.; McLafferty, F. W. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 10313–10317.
- (22) van de Waterbeemd, M.; Lössl, P.; Gautier, V.; Marino, F.; Yamashita, M.; Conti, E.; Scholten, A.; Heck, A. J. R. *Angew. Chem., Int. Ed.* **2014**, *53*, 9660–9664.
- (23) Greisch, J.-F.; Tamara, S.; Scheltema, R. A.; Maxwell, H. W. R.; Fagerlund, R. D.; Fineran, P. C.; Tetter, S.; Hilvert, D.; Heck, A. J. R. *Chem. Sci.* **2019**, *10*, 7163–7171.
- (24) Quaiter-Randall, E.; Joachimiak, A. *Chaperonin Protocols*; Schneider, C., Ed.; Methods in Molecular Biology; Springer: New York: Totowa, NJ, 2000; pp 29–39.
- (25) Voziyan, P. A.; Fisher, M. T. *Protein Sci.* **2000**, *9*, 2405.
- (26) van Duijn, E.; Bakkes, P. J.; Heeren, R. M. A.; van den Heuvel, R. H. H.; van Heerikhuizen, H.; van der Vies, S. M.; Heck, A. J. R. *Nat. Methods* **2005**, *2*, 371–376.
- (27) Sasaki, E.; Hilvert, D. *J. Phys. Chem. B* **2016**, *120*, 6089–6095.
- (28) Rosati, S.; Rose, R. J.; Thompson, N. J.; van Duijn, E.; Damoc, E.; Denisov, E.; Makarov, A.; Heck, A. J. R. *Angew. Chem., Int. Ed.* **2012**, *51*, 12992–12996.
- (29) Fort, K. L.; Dyachenko, A.; Potel, C. M.; Corradini, E.; Marino, F.; Barendregt, A.; Makarov, A. A.; Scheltema, R. A.; Heck, A. J. R. *Anal. Chem.* **2016**, *88*, 2303–2310.
- (30) Girod, M.; Biarc, J.; Enjalbert, Q.; Salvador, A.; Antoine, R.; Dugourd, P.; Lemoine, J. *Analyst* **2014**, *139*, 5523–5530.
- (31) Peters-Clarke, T. M.; Schauer, K. L.; Riley, N. M.; Lodge, J. M.; Westphall, M. S.; Coon, J. J. *Anal. Chem.* **2020**, *92*, 12363–12370.
- (32) Vasicek, L. A.; Ledvina, A. R.; Shaw, J.; Griep-Raming, J.; Westphall, M. S.; Coon, J. J.; Brodbelt, J. S. *J. Am. Soc. Mass Spectrom.* **2011**, *22*, 1105–1108.
- (33) Klein, J.; Carvalho, L.; Zaia, J. *Bioinformatics* **2018**, *34*, 3511–3518.

- (34) Klein, J.; Heckendorf, C.; Lukauskas, S. *mobiusklein/msdeisotope: Release v0.0.10*; Zenodo, 2019 <https://zenodo.org/record/3475687#.XnNv8HLTPY>.
- (35) Park, J.; Piehowski, P. D.; Wilkins, C.; Zhou, M.; Mendoza, J.; Fujimoto, G. M.; Gibbons, B. C.; Shaw, J. B.; Shen, Y.; Shukla, A. K.; Moore, R. J.; Liu, T.; Petyuk, V. A.; Tolić, N.; Paša-Tolić, L.; Smith, R. D.; Payne, S. H.; Kim, S. *Nat. Methods* **2017**, *14*, 909–914.
- (36) Colorado, A.; Shen, J. X.; Vartanian, V. H.; Brodbelt, J. *Anal. Chem.* **1996**, *68*, 4033–4043.
- (37) Boué, S. M.; Stephenson, J. L.; Yost, R. A. *Rapid Commun. Mass Spectrom.* **2000**, *14*, 1391–1397.
- (38) Tecklenburg, R. E.; Miller, M. N.; Russell, D. H. *J. Am. Chem. Soc.* **1989**, *111*, 1161–1171.
- (39) Vasicek, L.; Brodbelt, J. S. *Anal. Chem.* **2010**, *82*, 9441–9446.
- (40) Cotham, V. C.; Wine, Y.; Brodbelt, J. S. *Anal. Chem.* **2013**, *85*, 5577–5585.
- (41) Quick, M. M.; Mehaffey, M. R.; Johns, R. W.; Parker, W. R.; Brodbelt, J. S. *J. Am. Soc. Mass Spectrom.* **2017**, *28*, 1462–1472.
- (42) Vasicek, L. A.; Wilson, J. J.; Brodbelt, J. S. *J. Am. Soc. Mass Spectrom.* **2009**, *20*, 377–384.
- (43) Wilson, J. J.; Kirkovits, G. J.; Sessler, J. L.; Brodbelt, J. S. *J. Am. Soc. Mass Spectrom.* **2008**, *19*, 257–260.
- (44) Lancelot, G.; Mayer, R.; Hélène, C. *Biochim. Biophys. Acta, Nucleic Acids Protein Synth.* **1979**, *564*, 181–190.
- (45) Braunewell, K.-H.; Paul, B.; Altarche-Xifro, W.; Noack, C.; Lange, K.; Hofmann, A. *Aust. J. Chem.* **2010**, *63*, 350–356.
- (46) Hirsch, A. K. H.; Fischer, F. R.; Diederich, F. *Angew. Chem., Int. Ed.* **2007**, *46*, 338–352.
- (47) Parca, L.; Gherardini, P. F.; Helmer-Citterich, M.; Ausiello, G. *Nucleic Acids Res.* **2011**, *39*, 1231–1242.
- (48) Seki, A.; Coppinger, J. A.; Jang, C.-Y.; Yates, J. R.; Fang, G. *Science* **2008**, *320*, 1655–1658.
- (49) Hutterer, A.; Berdnik, D.; Wirtz-Peitz, F.; Žigman, M.; Schleiffer, A.; Knoblich, J. A. *Dev. Cell* **2006**, *11*, 147–157.
- (50) Eckerdt, F.; Maller, J. L. *Trends Biochem. Sci.* **2008**, *33*, 511–513.
- (51) Brunner, A. M.; Lössl, P.; Liu, F.; Huguet, R.; Mullen, C.; Yamashita, M.; Zabrouskov, V.; Makarov, A.; Altelaar, A. F. M.; Heck, A. J. R. *Anal. Chem.* **2015**, *87*, 4152–4158.
- (52) Kettenbach, A. N.; Schweppe, D. K.; Faherty, B. K.; Pechenick, D.; Pletnev, A. A.; Gerber, S. A. *Sci. Signaling* **2011**, *4*, rs5.
- (53) Jackson, S. A.; McKenzie, R. E.; Fagerlund, R. D.; Kieper, S. N.; Fineran, P. C.; Brouns, S. J. *J. Science* **2017**, *356*, No. eaal5056.
- (54) Rouillon, C.; Zhou, M.; Zhang, J.; Politis, A.; Beilsten-Edmands, V.; Cannone, G.; Graham, S.; Robinson, C. V.; Spagnolo, L.; White, M. F. *Mol. Cell* **2013**, *52*, 124–134.
- (55) Braig, K.; Joachimiakt, A.; Horwich, A. L.; Sigler, P. B. *Nature* **1994**, *371*, 9.
- (56) Rostom, A. A.; Robinson, C. V. *J. Am. Chem. Soc.* **1999**, *121*, 4718–4719.
- (57) Sobott, F.; Robinson, C. V. *Int. J. Mass Spectrom.* **2004**, *236*, 25–32.
- (58) Rose, R. J.; Damoc, E.; Denisov, E.; Makarov, A.; Heck, A. J. R. *Nat. Methods* **2012**, *9*, 1084–1086.
- (59) Belov, M. E.; Damoc, E.; Denisov, E.; Compton, P. D.; Horning, S.; Makarov, A. A.; Kelleher, N. L. *Anal. Chem.* **2013**, *85*, 11163–11173.
- (60) Li, H.; Nguyen, H. H.; Ogorzalek Loo, R. R.; Campuzano, I. D. G.; Loo, J. A. *Nature Chem.* **2018**, *10*, 139–148.
- (61) van de Waterbeemd, M.; Fort, K. L.; Boll, D.; Reinhardt-Szyba, M.; Routh, A.; Makarov, A.; Heck, A. J. R. *Nat. Methods* **2017**, *14*, 283–286.
- (62) Quack, M. *Infrared Phys.* **1989**, *29*, 441–466.